C-7 | Evolving Strategies in Lipid-Lowering Therapy Post-Coronary CT Angiogram: A Decadal Analysis at Aurora St. Luke Medical Center (2012-2022)

Coronary CT angiography (CCTA) has emerged as a transformative tool in cardiovascular imaging, significantly impacting the landscape of lipid-lowering therapy. Beyond its diagnostic capabilities, CCTA has become a catalyst for personalized medicine, influencing therapeutic strategies in managing CAD, particularly in lipid-lowering therapy. This investigation seeks to contribute to optimizing lipid-lowering strategies based on noninvasive coronary imaging. We conducted a retrospective analysis utilizing electronic health records at our center to investigate the impact of CCTA on lipid-lowering therapy trends. The study cohort comprised consecutive patients who underwent CCTA in the outpatient setting. Data on patient demographics and clinical characteristics, including pre-existing conditions and information on the status of lipid-lowering therapy, both prior to and following CCTA, were collected and examined. A total of 5,948 unique patients were included in this study. The mean age was 59 years; 54% of patients were female, and 62% had hyperlipidemia at the time of CCTA. Notably, 69.4% (4,129/5,948) were already on lipid-lowering therapy before the CCTA. Following CCTA, 19.4% (1,153/5,948) of patients experienced optimization in lipid-lowering therapy. Among those initially not on lipid-lowering therapy (1,189 patients), 30.5% (554 patients) initiated therapy based on CCTA findings. In contrast, among those already on lipid-lowering therapy (4,129 patients), 13.5% (559 patients) underwent intensification of their regimen. These findings highlight significant alterations in lipid management strategies prompted by CCTA results in the outpatient setting. This 10-year outpatient study reveals a significant impact of CCTA on lipid-lowering therapy. The findings highlight the pivotal role of CCTA in guiding therapeutic decisions, leading to the initiation or intensification of lipid-lowering therapy in nearly one-fifth of patients. This information underscores the clinical relevance of incorporating CCTA into lipid management strategies, contributing to personalized cardiovascular care and potentially reducing long-term cardiovascular risk.